Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -611.47% is 42% above its 5-year average of -1053.22%, near the high end of its 5-year range (-154400.00%–0.00%).
98.33% above its 12-month average of -36666.14%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -154400.00%.
NET PROFIT MARGIN
-611.47%
NET PROFIT MARGIN AVG TTM
-36666.14%
NET PROFIT MARGIN AVG 3Y
-720.93%
NET PROFIT MARGIN AVG 5Y
-1053.22%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+98.33%
CURRENT VS 3Y AVG
+15.18%
CURRENT VS 5Y AVG
+41.94%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 631 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Bolt Biotherapeutics, Inc.
Market Cap
$6.92M
Net Profit Margin
-611.47%
TTM Avg
-36666.14%
3Y Avg
-720.93%
5Y Avg
-1053.22%
Market Cap
$7.13M
Net Profit Margin
-6523.04%
TTM Avg
-4247.49%
3Y Avg
-2263.82%
5Y Avg
-1493.48%
Market Cap
$6.70M
Net Profit Margin
-10978.48%
TTM Avg
-12422.83%
3Y Avg
-10763.38%
5Y Avg
-10131.90%
Market Cap
$6.67M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$7.20M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-19.45%
5Y Avg
-19.45%
Market Cap
$7.20M
Net Profit Margin
-4791.48%
TTM Avg
-2970.23%
3Y Avg
-7387.99%
5Y Avg
-5910.39%
Market Cap
$7.25M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$7.27M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-287.91%
5Y Avg
-676.70%
Market Cap
$7.32M
Net Profit Margin
-1977.59%
TTM Avg
-1280.67%
3Y Avg
-1780.71%
5Y Avg
-1415.68%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | $6.92M | -611.47% | -36666.14% | -720.93% | -1053.22% |
| Co-Diagnostics, Inc. (CODX)vs › | $7.13M | -6523.04% | -4247.49% | -2263.82% | -1493.48% |
| Aclarion, Inc. (ACON)vs › | $6.70M | -10978.48% | -12422.83% | -10763.38% | -10131.90% |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.67M | 0.00% | 0.00% | 0.00% | 0.00% |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.20M | 0.00% | 0.00% | -19.45% | -19.45% |
| Mangoceuticals, Inc. (MGRX)vs › | $7.20M | -4791.48% | -2970.23% | -7387.99% | -5910.39% |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $7.25M | 0.00% | 0.00% | 0.00% | 0.00% |
| KALA BIO, Inc. (KALA)vs › | $7.27M | 0.00% | 0.00% | -287.91% | -676.70% |
| Longeveron Inc. (LGVN)vs › | $7.32M | -1977.59% | -1280.67% | -1780.71% | -1415.68% |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.33M | -0.61% | -82.77% | -131.16% | -372.00% |
Operating Margin
-450.1%
Net Profit Margin
-611.5%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -154400.00% |
| 2026-03-31 | -27861.54% |
| 2025-12-31 | -265.24% |
| 2025-09-30 | -329.37% |
| 2025-06-30 | -474.56% |
| 2025-03-31 | -903.44% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | -1330.06% |
| 2024-06-30 | -1662.35% |
| 2024-03-31 | -204.99% |
| 2023-12-31 | -857.01% |
| 2023-09-30 | -643.08% |
| 2023-06-30 | -1260.08% |
| 2023-03-31 | -929.90% |
| 2022-12-31 | -1417.22% |
| 2022-09-30 | -1030.26% |
| 2022-06-30 | -1626.99% |
| 2022-03-31 | -2912.42% |
| 2021-12-31 | -5345.87% |
| 2021-09-30 | -3111.04% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | -16505.97% |
| 2020-03-31 | -5264.02% |
| 2019-12-31 | -14403.08% |
| 2019-09-30 | -5937.19% |
| 2019-06-30 | -48072.41% |
| 2019-03-31 | -48072.41% |
